Found 6 hits for monomerid = 354687 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Muscarinic acetylcholine receptor M3
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
Human M3 receptor membranes (15 μg/well) from Perkin Elmer are incubated with 0.52 nM Scopolamine Methyl Chloride, [N-methyl-3H] with or without... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B2
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <1 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
PDE4B2 activity is detected using the LANCE Ultra cAMP homogeneous time resolved fluorescence resonance energy transfer (TR-FRET) assay from Perkin E... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B2
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
PDE4B2 activity is detected using the LANCE Ultra cAMP homogeneous time resolved fluorescence resonance energy transfer (TR-FRET) assay from Perkin E... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B2
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | PDB
UniProtKB/SwissProt
UniProtKB/TrEMBL
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
PDE4B2 activity is detected using the LANCE Ultra cAMP homogeneous time resolved fluorescence resonance energy transfer (TR-FRET) assay from Perkin E... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
Muscarinic acetylcholine receptor M3
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
Human M3 receptor membranes (15 μg/well) from Perkin Elmer are incubated with 0.52 nM Scopolamine Methyl Chloride, [N-methyl-3H] with or without... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
Muscarinic acetylcholine receptor M3
(Homo sapiens (Human)) | BDBM354687
(US9809582, Example 32 | US9809582, Example 34 | US...)Show SMILES COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC2CC(C2)(C(=O)OC2CCN(C)CC2)c2ccccc2)s1 |r,wU:10.22,(-8.04,-9.05,;-6.71,-9.82,;-5.37,-9.05,;-4.04,-9.82,;-2.7,-9.05,;-2.7,-7.51,;-4.04,-6.74,;-5.37,-7.51,;-6.71,-6.74,;-8.04,-7.51,;-1.37,-6.74,;-.04,-7.51,;1.3,-6.74,;1.3,-5.2,;-.04,-4.43,;2.63,-4.43,;3.96,-5.2,;5.3,-4.43,;3.96,-6.74,;2.63,-7.51,;2.63,-9.05,;-1.37,-5.2,;-2.7,-4.43,;-4.04,-5.2,;-2.7,-2.89,;-3.95,-1.98,;-3.47,-.52,;-1.93,-.52,;-1.03,.73,;-1.66,2.14,;-.89,3.47,;.6,3.87,;.2,5.35,;-1.28,4.96,;1.69,4.96,;2.78,6.05,;2.09,3.47,;3.58,3.07,;3.98,1.58,;5.46,1.18,;6.55,2.27,;8.04,1.87,;6.15,3.76,;4.67,4.16,;-.2,6.84,;.89,7.93,;.49,9.42,;-.99,9.82,;-2.08,8.73,;-1.68,7.24,;-1.46,-1.98,)| Show InChI InChI=1S/C38H41Cl2N3O7S/c1-42-15-13-27(14-16-42)49-37(45)38(25-7-5-4-6-8-25)19-26(20-38)41-21-28-10-12-35(51-28)36(44)50-33(18-29-30(39)22-43(46)23-31(29)40)24-9-11-32(47-2)34(17-24)48-3/h4-12,17,22-23,26-27,33,41H,13-16,18-21H2,1-3H3/t26?,33-,38?/m0/s1 | Reactome pathway
KEGG
UniProtKB/SwissProt
UniProtKB/TrEMBL
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
CHIESI FARMACEUTICI S.p.A.
US Patent
| Assay Description
Human M3 receptor membranes (15 μg/well) from Perkin Elmer are incubated with 0.52 nM Scopolamine Methyl Chloride, [N-methyl-3H] with or without... |
US Patent US9809582 (2017)
BindingDB Entry DOI: 10.7270/Q2H1345N |
More data for this
Ligand-Target Pair | |
Search and Browse
